<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00122473</url>
  </required_header>
  <id_info>
    <org_study_id>ADO/VOD DFSP 001</org_study_id>
    <secondary_id>CSTI571BDE25</secondary_id>
    <nct_id>NCT00122473</nct_id>
  </id_info>
  <brief_title>Imatinib in Dermatofibrosarcoma Protuberans (DFSP)</brief_title>
  <official_title>Open-label Trial of Glivec® (Imatinib Mesylate) in Patients With Primary or Recurrent Dermatofibrosarcoma Protuberans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermatologic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermatologic Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether imatinib is effective in the treatment of
      primary and recurrent dermatofibrosarcoma protuberans (DFSP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is aimed to investigate the efficacy of imatinib (Glivec) in the treatment of
      primary and locally relapsed dermatofibrosarcoma protuberans (DFSP). DFSP is a cutaneous
      neoplasm well known for its overexpression of the platelet-derived growth factor (PDGF).
      Herein, imatinib provides a systemic treatment option that offers the possibility of a
      reduction of the wide surgical margins used today in surgery of primary DFSP, or even of a
      complete avoidance of surgical treatment in this disease. Since imatinib exerts its function
      via interference with protein tyrosine kinase activities, it inhibits the platelet-derived
      growth factor receptor (PDGF-R) signaling cascade that plays a crucial role in the
      pathogenesis and tumor growth of DFSP. Since imatinib has been shown to shrink metastatic
      lesions of DFSP, there is a strong rationale to expect that it also decreases cell
      proliferation and tumor growth in primary DFSP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date>January 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response at 6 and 12 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of relapse within the first 2 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of tumor response with cytogenetic and receptor expression status</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Dermatofibrosarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib (Glivec)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of primary or recurrent dermatofibrosarcoma protuberans

          -  Measurable tumor parameters (by magnetic resonance imaging [MRI])

          -  Patient &gt;/= 18 years of age

          -  ECOG performance status &lt; 3

          -  Adequate organ function

          -  Patients must be able to swallow capsules

          -  Female patients of childbearing potential must have negative pregnancy test

          -  Written, voluntary, informed consent; must include investigational use of tumor tissue
             biopsies.

        Exclusion Criteria:

          -  Any evidence of distant metastases

          -  Patient has received any other investigational agents within 28 days of first day of
             study drug dosing

          -  Patient is &lt; 5 years free of another primary malignancy except basal cell skin cancer
             or cervical carcinoma in situ

          -  Grade III/IV cardiac problems as defined by the New York Heart Association

          -  Severe and/or uncontrolled medical disease

          -  Known diagnosis of human immunodeficiency virus (HIV) infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selma Ugurel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Cancer Unit, German Cancer Research Center Heidelberg and Department of Dermatology, University Hospital of Mannheim, Mannheim, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk Schadendorf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Cancer Unit, German Cancer Research Center Heidelberg and Department of Dermatology, University Hospital of Mannheim, Mannheim, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Cancer Unit, German Cancer Research Center and Department of Dermatology, University Hospital of Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, ElbeKliniken - Klinikum Buxtehude</name>
      <address>
        <city>Buxtehude</city>
        <state>Niedersachsen</state>
        <zip>21614</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, The Saarland University Hospital</name>
      <address>
        <city>Homburg/Saar</city>
        <state>Saarland</state>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, Martin-Luther-University Halle-Wittenberg</name>
      <address>
        <city>Halle/Saale</city>
        <state>Sachsen-Anhalt</state>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005 Feb 1;23(4):866-73.</citation>
    <PMID>15681532</PMID>
  </reference>
  <reference>
    <citation>Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs. 2005 Apr;16(4):461-6.</citation>
    <PMID>15746584</PMID>
  </reference>
  <reference>
    <citation>Price VE, Fletcher JA, Zielenska M, Cole W, Viero S, Manson DE, Stuart M, Pappo AS. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer. 2005 May;44(5):511-5.</citation>
    <PMID>15503291</PMID>
  </reference>
  <reference>
    <citation>Mizutani K, Tamada Y, Hara K, Tsuzuki T, Saeki H, Tamaki K, Matsumoto Y. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol. 2004 Jul;151(1):235-7. Review.</citation>
    <PMID>15270901</PMID>
  </reference>
  <reference>
    <citation>McArthur G. Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol. 2004 Apr;31(2 Suppl 6):30-6. Review.</citation>
    <PMID>15176002</PMID>
  </reference>
  <reference>
    <citation>Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer. 2003 May;37(1):1-19. Review.</citation>
    <PMID>12661001</PMID>
  </reference>
  <reference>
    <citation>Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer. 2002 Aug 20;100(6):623-6.</citation>
    <PMID>12209598</PMID>
  </reference>
  <reference>
    <citation>Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 2002 Sep 1;20(17):3586-91.</citation>
    <PMID>12202658</PMID>
  </reference>
  <reference>
    <citation>Sjöblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 2001 Aug 1;61(15):5778-83.</citation>
    <PMID>11479215</PMID>
  </reference>
  <reference>
    <citation>Greco A, Roccato E, Miranda C, Cleris L, Formelli F, Pierotti MA. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer. 2001 May 1;92(3):354-60.</citation>
    <PMID>11291071</PMID>
  </reference>
  <reference>
    <citation>Shimizu A, O'Brien KP, Sjöblom T, Pietras K, Buchdunger E, Collins VP, Heldin CH, Dumanski JP, Ostman A. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 1999 Aug 1;59(15):3719-23.</citation>
    <PMID>10446987</PMID>
  </reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2005</study_first_submitted>
  <study_first_submitted_qc>July 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2005</study_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2011</last_update_posted>
  <keyword>Dermatofibrosarcoma</keyword>
  <keyword>Imatinib</keyword>
  <keyword>Tyrosine Kinase Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatofibrosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

